{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:21:43Z","timestamp":1762507303873},"reference-count":25,"publisher":"Editorial Committee of Annals of Thoracic and Cardiovascular Surgery","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ATCS","Ann Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2018]]},"DOI":"10.5761\/atcs.oa.17-00192","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T22:23:12Z","timestamp":1516659792000},"page":"81-88","source":"Crossref","is-referenced-by-count":12,"title":["Is Pleurectomy\/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience"],"prefix":"10.5761","volume":"24","author":[{"given":"Takuro","family":"Miyazaki","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoshi","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Kamohara","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Hatachi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagayasu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3757","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tural Onur S, Sokucu SN, Dalar L, et al. Are neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag 2016; 12: 651-6.","DOI":"10.2147\/TCRM.S104077"},{"key":"2","unstructured":"2) The prevalence of malignant pleural mesothelioma. http:\/\/ganjoho.jp\/public\/cancer\/mesothelioma\/index.html. Accessed 11 Oct 2017. (in Japanese)"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg 2011; 40: 298-303.","DOI":"10.1016\/j.ejcts.2010.12.024"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hasegawa S, Okada M, Tanaka F, et al. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). Int J Clin Oncol. 2016; 21: 523-30.","DOI":"10.1007\/s10147-015-0925-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12: 763-72.","DOI":"10.1016\/S1470-2045(11)70149-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kostron A, Friess M, Inci I, et al. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy\/decortication for mesothelioma patients\u2020. Interact Cardiovasc Thorac Surg 2017; 24: 740-6.","DOI":"10.1093\/icvts\/ivw422"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Infante M, Morenghi E, Bottoni E, et al. Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2016; 50: 1077-82.","DOI":"10.1093\/ejcts\/ezw215"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Batirel HF, Metintas M, Caglar HB, et al. Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2016; 151: 478-84.","DOI":"10.1016\/j.jtcvs.2015.09.121"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 2015; 99: 472-80.","DOI":"10.1016\/j.athoracsur.2014.09.056"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Shimokawa M, Hasegawa S, Fukuoka K, et al. A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy\/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma. Jpn J Clin Oncol 2013; 43: 575-8.","DOI":"10.1093\/jjco\/hyt035"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Verma V, Ahern CA, Berlind CG, et al. National cancer database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma. J Thorac Oncol 2017; 12: 1704-14.","DOI":"10.1016\/j.jtho.2017.08.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Takuwa T, Hasegawa S. Current surgical strategies for malignant pleural mesothelioma. Surg Today 2016; 46: 887-94.","DOI":"10.1007\/s00595-015-1275-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005; 23: 184-9.","DOI":"10.1200\/JCO.2005.07.050"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nelson DB, Rice DC, Niu J, et al. Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis. J Clin Oncol 2017; 35: 3354-62.","DOI":"10.1200\/JCO.2017.73.8401"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Takamori S, Toyokawa G, Taguchi K, et al. The controlling nutritional status score is a significant independent predictor of poor prognosis in patients with malignant pleural mesothelioma. Clin Lung Cancer 2017; 18: e303-13.","DOI":"10.1016\/j.cllc.2017.01.008"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Miyazaki T, Yamasaki N, Tsuchiya T, et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 2015; 47: e140-5.","DOI":"10.1093\/ejcts\/ezu514"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today 2017; 47: 836-43.","DOI":"10.1007\/s00595-016-1448-8"},{"key":"18","unstructured":"18) Tagawa T, Anraku M, Morodomi Y, et al. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. J Thorac Dis 2015; 7: 1898-906."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Grosso F, Steele N, Novello S, et al. Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial. J Clin Oncol 2017; 35: 3591-600.","DOI":"10.1200\/JCO.2017.72.9012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405-14.","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017; 18: 623-30.","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Friedberg JS, Simone CB, Culligan MJ, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg 2017; 103: 912-9.","DOI":"10.1016\/j.athoracsur.2016.08.071"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Pass H, Giroux D, Kennedy C, et al. The IASLC mesothelioma staging project: improving staging of a rare disease through international participation. J Thorac Oncol 2016; 11: 2082-8.","DOI":"10.1016\/j.jtho.2016.09.123"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nowak AK, Chansky K, Rice DC, et al. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol 2016; 11: 2089-99.","DOI":"10.1016\/j.jtho.2016.08.147"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Rusch VW, Gill R, Mitchell A, et al. A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma. Ann Thorac Surg 2016; 102: 1059-66.","DOI":"10.1016\/j.athoracsur.2016.06.069"}],"container-title":["Annals of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/24\/2\/24_oa.17-00192\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T17:32:26Z","timestamp":1570642346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/24\/2\/24_oa.17-00192\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5761\/atcs.oa.17-00192","relation":{},"ISSN":["1341-1098","2186-1005"],"issn-type":[{"value":"1341-1098","type":"print"},{"value":"2186-1005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}